Hong-Uyen Hua, MD

A panel of ophthalmologists discuss strategies for improving patient outcomes in retinal vein occlusion with anti-VEGF and other therapies.

Optimizing Treatment Outcomes in Retinal Vein Occlusion

Videos

Optimizing Treatment Outcomes in Retinal Vein Occlusion (RVO)

To watch the video series component of this episode, click here.

Podcasts

Retinal vein occlusion (RVO) presents significant challenges in ophthalmology, necessitating careful treatment selection and diagnostic approaches. Understanding the role of angiopoietin-2 (Ang-2) is crucial in managing RVO, as it influences disease progression and treatment outcomes. Steroids play a pivotal role in RVO management, offering therapeutic benefits but requiring careful consideration of potential side effects. Patient education is essential to ensure adherence to treatment plans and improve overall outcomes. Comprehensive management of RVO involves a multidisciplinary approach, integrating diagnostics, pharmacotherapy, and patient engagement strategies.

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and DME

1:00 Suboptimal Response
6:30 Treatment Strategy
11:10 Response to New Therapies
14:00 Imaging for Monitoring
18:30 Role of Ang-2

Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and Diabetic Macular Edema

To watch the video series component of this episode, click here. 

1:12 Suboptimal Response
6:42 Treatment Strategy
11:22 Response to New Therapies
14:12 Imaging for Monitoring
18:42 Role of Ang-2

Recent advancements in the management of lung cancer brain metastases have significantly improved patient outcomes. The integration of novel therapies, including targeted treatments and immunotherapy, has shown promise in enhancing response rates and prolonging survival. Imaging techniques play a crucial role in monitoring treatment efficacy and disease progression. Angiopoietin-2 (Ang-2) has emerged as a potential biomarker for assessing treatment response and guiding therapeutic decisions. These developments underscore the importance of a multidisciplinary approach in optimizing treatment strategies and improving the quality of life for patients with brain metastases from lung cancer.

Hong-Uyen Hua, MD

Articles